Short answer
RET and VHL both show up in pheochromocytoma workups, but they answer different questions. RET is the MEN2 gene, so it brings medullary thyroid cancer and parathyroid disease into the conversation alongside adrenal risk. VHL is a broader multi-organ tumor syndrome, where kidney cancer, hemangioblastomas, pancreatic lesions, and pheochromocytoma can all sit in the same family pattern.
The same pheochromocytoma can therefore point in very different directions depending on which other organs, family members, and age patterns are present.
How they differ
| Pattern | RET clue | VHL clue |
|---|---|---|
| Syndrome context | MEN2, medullary thyroid cancer, parathyroid disease | Kidney tumors, hemangioblastomas, pancreatic lesions |
| Pheochromocytoma pattern | Often adrenal and sometimes bilateral depending on variant | Adrenal pheochromocytoma can occur with other VHL findings |
| Family action | RET-specific cascade testing and thyroid-risk planning | VHL-specific surveillance across multiple organs |
| What a negative result means | Does not exclude other PPGL genes or another RET family issue | Does not exclude other hereditary renal or PPGL genes |
When RET is more likely
RET becomes more likely when medullary thyroid cancer, elevated calcitonin, or a known family RET variant is in the picture. GeneReviews for MEN2 emphasizes that RET gain-of-function variants drive MEN2A, familial medullary thyroid carcinoma, and MEN2B. Those syndromes carry thyroid-centered surveillance questions that VHL does not.
That is why RET testing is often not just about the adrenal tumor. It can change thyroid surgery timing, calcitonin monitoring, and which relatives need targeted testing.
When VHL is more likely
VHL becomes more likely when the family history or tumor pattern includes kidney cancer, hemangioblastomas of the brain, spinal cord, or retina, pancreatic cysts or neuroendocrine tumors, or endolymphatic sac tumors. GeneReviews and MedlinePlus Genetics both describe VHL as a multi-organ syndrome, and pheochromocytoma is only one part of that picture.
So if the case looks bigger than adrenal disease, VHL often moves up the list quickly.
When a negative result does not settle the question
A negative RET result does not rule out hereditary PPGL, and a negative VHL result does not rule out MEN2 or another PPGL syndrome. SDHx genes, TMEM127, MAX, NF1, and EPAS1 can still explain a pheochromocytoma pattern. NCI’s PDQ and the broader PPGL reviews stress that the family history and tumor pattern still matter after genetics comes back.
Tumor-only results also need caution. A change in the tumor does not automatically mean a germline family risk.
Family testing and surveillance
If a pathogenic germline RET variant is found, relatives may need targeted testing and MEN2-specific surveillance, especially for thyroid cancer risk. If a pathogenic germline VHL variant is found, surveillance broadens to kidneys, brain/spine, retina, pancreas, adrenal glands, and other VHL-associated sites. The organ list changes with the gene, which is why this comparison matters clinically.
In both cases, a genetics specialist is often the right person to map the test result to the right family members and surveillance schedule.
Questions to ask
- Was the result germline, tumor-only, or paired tumor-normal?
- Is the thyroid picture leaning toward MEN2, or is the case broader and more VHL-like?
- Does the assay include deletion/duplication analysis and full coverage of the relevant gene?
- Which relatives need targeted testing first?
- What surveillance should be started now instead of waiting for the next visit?
- Could another PPGL gene still explain the result if RET or VHL is negative?
FAQ
What is the main difference between RET and VHL testing?
RET testing is usually looking for MEN2, especially medullary thyroid cancer risk and pheochromocytoma. VHL testing is looking for a broader multi-organ syndrome that can include kidney cancer, CNS or retinal hemangioblastomas, pancreatic lesions, and pheochromocytoma.
When does RET become more likely?
RET becomes more likely when medullary thyroid cancer, elevated calcitonin, parathyroid disease, or a known family RET variant is present. MEN2A and MEN2B each bring distinct surveillance and family-testing questions.
When does VHL become more likely?
VHL becomes more likely when kidney cancer, hemangioblastomas, pancreatic lesions, endolymphatic sac tumors, or a family pattern of multi-organ VHL findings is present.
Does a negative result rule out hereditary PPGL?
No. A negative RET or VHL result does not rule out hereditary PPGL. Other genes such as SDHx, TMEM127, MAX, NF1, and EPAS1 can still explain the tumor pattern.
Should relatives be tested if one gene is positive?
If a pathogenic germline variant is confirmed, first-degree relatives are often offered targeted testing for the known family variant. If the result is tumor-only or uncertain, the family plan is different.
What follow-up tests matter after either result?
Thyroid, adrenal, kidney, and neuroimaging follow-up can matter depending on the gene. Genetics helps guide surveillance, but the family history and tumor features still have to be reviewed.